2月6日,阿斯利康公布2024年业绩,总营收540.73亿美元(+21%),其中产品收入509.38亿美元(+19%);全年研发投入135.83亿美元,同比增长25%。从地区分布来看,2024年美国市场收入232.35亿美元(+22%),新兴市场收入136.75亿美元(+22%),其中中国区收入64.13亿美元(+11%),占据阿斯利康全球市场份额的12%。阿斯利康将业务划分为肿瘤、CVRM(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.